1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Philogen Raises €62m To Advance Pipeline, Expand GMP Capacity

 
• By Sten Stovall

Philogen CEO Dario Neri tells Scrip the company he co-founded now has two oncology products in Phase III development and might consider partnering them for certain indications.

R&D
Philogen develops drugs for the treatment of angiogenesis-related disorders • Source: Shutterstock

Swiss-Italian integrated biotech Philogen SPA will use €62m in freshly injected money from new and existing investors to advance its wholly owned pipeline and expand its GMP production capacity while also continuing to progress assets that are in development in collaborations with a number of big pharmaceutical companies, the privately owned group’s CEO told Scrip.

Key priorities will be completing current Phase III trials for Philogen’s two most advanced assets: Daromun, which is being investigated...

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.